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Abstract: NK-5962 is a key component of photoelectric dye-based retinal prosthesis (OUReP). In 
testing the safety and efficacy, NK-5962 was safe in all tests for the biological evaluation of medical 
devices (ISO 10993) and effective in preventing retinal cells from death even under dark conditions. 
The long-term implantation of the photoelectric dye-coupled polyethylene film in the subretinal 
space of hereditary retinal dystrophic (RCS) rats prevented neurons from apoptosis in the adjacent 
retinal tissue. The intravitreous injection of NK-5962 in the eyes of RCS rats, indeed, reduced the 
number of apoptotic cells in the retinal outer nuclear layer irrespective of light or dark conditions. 
In this study, we reviewed the in vitro and in vivo evidence of neuroprotective effect of NK-5962 
and designed pharmacokinetic experiments. The in vitro IC50 of 1.7 μM, based on the protective 
effect on retinal cells in culture, could explain the in vivo EC50 of 3 μM that is calculated from con-
centrations of intravitreous injection to prevent retinal neurons from apoptosis. Pharmacokinetics 
of NK-5962 showed that intravenous administration, but not oral administration, led to the effective 
concentration in the eye of rats. NK-5962 would be a candidate drug for delaying the deterioration 
of retinal dystrophy, such as retinitis pigmentosa. 
Keywords: NK-5962; photoelectric dye; apoptosis; retinal neuron; neuroprotection; pharmacokinetics; 
ADME; phototoxic/photosensitive assay; reactive oxygen species assay; photosafety 
 
1. Introduction 
Retinitis pigmentosa is a hereditary disease which shows progressive loss of retinal 
photoreceptor cells usually at first in the peripheral retina. Patients with retinitis pigmen-
tosa experience the slowly progressive constriction of the visual field caused by peripheral 
retinal dystrophy and frequently end up with the loss of the vision by the macular in-
volvement. Up to this point in time, there has been no drug clinically available to stop or 
slow down the deterioration of retinitis pigmentosa. A best candidate would be a drug 
with safety in terms of long-term administration, which could prevent retinal neurons 
including photoreceptor cells from apoptotic death. A photoelectric dye, NK-5962, would 
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be a candidate drug for this purpose. In this article, we review our previous results on 
neuroprotection with NK-5962 and present new data on pharmacokinetics of NK-5962. 
2. Photoelectric Dye NK-5962 
A photoelectric dye, 2-[2-[4-(dibutylamino)phenyl]ethenyl]-3-carboxymethylbenzo-
thiazolium bromide (NK-5962, Hayashibara, Inc., Okayama, Japan), generates electric po-
tential in response to light and is used as a key component of photoelectric dye-based 
retinal prosthesis designated as OUReP (Okayama University Retinal Prosthesis) (Figure 
1) [1–3]. The process of producing OUReP consists in thin films made from polyethylene 
powder and exposed to fuming nitric acid to introduce carboxyl moieties on the film sur-
face. Photoelectric dye molecules are coupled to carboxyl moieties of the polyethylene 
film surface via ethylenediamine, as described previously [4–6]. The fuming nitric acid-
treated only polyethylene film and the photoelectric dye-coupled polyethylene films were 
designated as the plain films and the dye-coupled films, respectively. Films were manu-
factured in a quality management system at a clean-room facility in Okayama University 
Incubator. No toxicity of the dye-coupled film was proven in all tests for the biological 
evaluation of medical devices, which is based on International Standard ISO 10993 (data 
not shown). In addition, the photoelectric dye NK-5962 was not toxic in the cytotoxicity 
test, skin sensitization test, genetic toxicity tests (bacterial reverse mutation test, human 
chromosomal aberration test), eye irritation test, and acute and repeated-dose systemic 
toxicity tests. 
 
Figure 1. Overview of photoelectric dye-based retinal prosthesis (OUReP). Photoelectric dye NK-5962 molecules are chem-
ically coupled to the polyethylene film surface. Light-evoked electric potential changes are recorded by a Kelvin probe on 
the dye-coupled film surface. The dye-coupled film can be implanted by a disposable injector (OUReP Injector) into the 
subretinal space of intentional retinal detachment during vitreous surgery. 
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The dye-coupled films were proven to show light-evoked electric potential changes 
on their surface in the recording by Kelvin probe system [7,8]. The dye-coupled films were 
implanted in the subretinal space of hereditary retinal dystrophic rats (Royal College of 
Surgeons (RCS) rats) and behavior tests as well as electroretinographic and visual evoked 
potential recordings proved the efficacy of the dye-coupled films compared with the plain 
films [9–12]. As for the efficacy in in vivo large animal experiments, the dye-coupled films 
were implanted by vitreous surgery in the subretinal space of monkey eyes with macular 
degeneration and the visual evoked potential recordings that showed the recovery of the 
amplitude, which had been attenuated by the macular degeneration, in the 6 months after 
implantation [13]. As for the efficacy in in vitro testing, dystrophic retinal tissues isolated 
from RCS rats [8] and hereditary retinal dystrophic rd1 mice [14] were proven to induce 
light-evoked action potential spikes in the recording by a multielectrode array system. 
The other group of researchers recorded light-evoked changes in membrane action poten-
tials in neurons, which were cultured on the NK-5962-conjugated indium tin oxide sub-
strate surface [15]. As for safety, the dye-coupled films were implanted by vitreous sur-
gery in the subretinal space of canine [16] and rabbit eyes [17] to prove surgical safety. 
Furthermore, disposable injectors were designed to implant the dye-coupled films into 
the subretinal space of the eyes in a safe and efficient manner [18,19]. From the viewpoint 
of materials science, polyethylene film surface was designed to induce lesser glial re-
sponses in the subretinal implantation [20]. 
In testing the safety of the photoelectric dye NK-5962, we found that the photoelectric 
dye, in itself, likely protected retinal neurons from death by apoptosis in vitro, even under 
dark conditions [21]. Furthermore, we noted that the long-term implantation of the pho-
toelectric dye-coupled polyethylene film in the subretinal space of RCS rats prevented 
retinal neurons from apoptosis in the adjacent retinal tissue [10]. The intravitreous injec-
tion of NK-5962 in the eyes of RCS rats, indeed, reduced the number of apoptotic cells in 
the retinal outer nuclear layer irrespective of light or dark conditions [22]. 
In the following sections, we firstly review the in vitro evidence available [21] in Sec-
tions 3 and 4. In Section 5, the in vivo evidence regarding the neuroprotective effect of 
NK-5962 in our previous study [22] is examined. We then present the design of pharma-
cokinetic experiments for NK-5962 as a candidate drug towards the neuroprotection in 
Sections 6, demonstrated the pharmacokinetic results regarding the in vitro ADME assays 
in Section 7, and the in vivo administration in Section 8. We finally show the novel stand-
ardized testing for reactive oxygen species assay in Section 9. The following sections are 
independent with one another in that they have separate Methods and Results in each 
section. The structure of the article would allow readers to evaluate how the results were 
obtained by the use of different methods in each experiment. 
3. Cytotoxicity Assay using Mixed Culture of Retinal Neurons and Glial Cells 
3.1. Methods 
Egg shells (Fukuda Breeders Co., Ltd., Okayama, Japan) were disinfected with 70% 
alcohol and 12-day-old chick embryos were removed from a small opening. The eyes at 
this embryonic stage were used because the outer segments of the retinal photoreceptor 
cells had not yet been developed. The eyes were enucleated and cut at the midperiphery 
of the globe and the anterior halves were removed together with the vitreous. The neuro-
sensory retina at this embryonic stage could easily be peeled off from the eye cup. After 
peeling, retinal tissues were incubated in 0.25% trypsin, 1 mM ethylenediaminetetraacetic 
acid (EDTA) in Ca2+, and Mg2+-free Hanks’ balanced salt solution (HBSS) to disperse reti-
nal cells. After centrifugation, the retinal cells were washed with Dulbecco’s modified Ea-
gle’s medium (DMEM) and seeded at a concentration of 3.5 × 105 cell/mL in poly-L-lysine-
coated wells of a 96-well multidish containing DMEM supplemented with 10% fetal bo-
vine serum (FBS), 100 mg/L streptomycin, and 100 mg/L ampicillin. 
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In order to determine the types of cells, either neurons or glial cells derived from 
neurosensory retinal tissues, retinal cells following 2-day culture were stained for neuron-
specific enolase and glial fibrillary acidic protein by immunocytochemistry. The majority 
of retinal cells at day 2 of the culture were neurons mixed with a small number of glial 
cells (Figure 2). 
 
Figure 2. Cell viability assay for NK-5962 using chick retinal cells including neurons and glial cells. 
Top: Immunocytochemistry of retinal cells isolated from 12-day embryonic chick eyes and cultured 
for 2 days under light exposure for 9 h daily in the presence of NK-5962 at 1.6 × 10−5 M concentration. 
Neurons (red cells stained for neuron-specific enolase) in the left panel are the predominant popu-
lation compared with a small number of glial cells (green cells stained for glial fibrillary acidic pro-
tein) in the right panel. Bottom: The percentage of dead retinal cells cultured for 2 days either under 
protection from light or under light with a fluorescent lamp at 230 lux for 9 h daily in the absence 
or the presence of NK-5962 at the concentrations of 1.6 × 10−5 M, 1.6 × 10−6 M, and 1.6 × 10−7 M. The 
percentage of dead cells is significantly smaller at a higher concentration of NK-5962 (P = 0.0183, 
two-factor ANOVA), while the percentage of dead cells is not significantly different between the 
dark condition and the light condition (P = 0.3102). T bars indicate standard deviation. Modified 
from reference [21]. 
Retinal cells at a concentration of 3.5 × 105 cell/mL in 220 μL of DMEM with 10% FBS 
were cultured together with 20 μL of varying concentrations of NK-5962 for 2 days either 
under protection from light or under light from a fluorescent lamp at 230 lux for 9 h daily. 
The final concentrations of NK-5962 in the solution were 1.6 × 10−5, 1.6 × 10−6, and 1.6 × 10−7 
M. Cells were then incubated for 15 min with SYTO 10 Green fluorescent nucleic acid stain 
and DEAD Red nucleic acid stain (LIVE/DEAD Reduced Biohazard Viability/Cytotoxicity 
Kit: Molecular Probes; Thermo Fisher Scientific, Waltham, MA, USA) in HEPES-buffered 
saline. After being fixed with 4% glutaraldehyde in HEPES-buffered saline, live cells and 
dead cells were visualized with a 100 W mercury lamp as a light source under a fluores-
cence inverted microscope through a set of FITC and PI filters (Olympus IX71; Olympus 
Life Sciences, Tokyo, Japan). Images in the center of each well were captured with a CCD 
camera and stored in a computer. Three wells were assigned to each condition of incuba-
tion in one series of experiments and the entire procedure was repeated three times on 
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different days to obtain nine results for each condition. Green live cells (stained with SYTO 
10 Green) and orange dead cells (stained with both SYTO10 Green and DEAD RED) in the 
images for each well were counted and the percentage of dead cells to the total cells was 
analyzed statistically (Figure 2) [21]. 
3.2. Results 
At day 2 of culture, live cells and dead cells were stained for cell viability and cyto-
toxicity analysis. The majority of retinal cells were alive with only a few dead cells under 
the dark condition or the light condition in the presence or the absence of NK-5962 (Figure 
2). The percentage of dead cells was significantly smaller at higher concentrations of NK-
5962 (P = 0.0183, two-factor analysis of variance (ANOVA), Table 1), while the percentage 
of dead cells was not significantly different between the dark condition and the light con-
dition (P = 0.3102) [21].  
Table 1. Live retinal cells and dead cells in each experiment under protection from light or under light for 9 h daily in the 
absence or the presence of NK-5962 at varying concentrations. Modified from reference [21]. 
 The Number of Dead Cells/The Number of Live Cells 























0 Yes 13/242(5.0) 6/214(2.7) 9/257(3.3) 5/85(5.5) 2/138(1.4) 2/129(1.5) 3/133(2.2) 1/186(0.5) 8/272(2.9) 
0 No 0/576(0) 17/457(3.5) 12/239(4.7) 4/166(2.3) 12/224(5.0) 1/247(0.4) 3/171(1.7) 10/253(3.8) 3/117(2.5) 
1.6 × 10−5 M Yes 0/254(0) 2/400(0.5) 1/397(0.3) 0/460(0) 4/207(1.9) 1/292(0.3) 5/153(3.2) 5/164(3.0) 2/152(1.3) 
1.6 × 10−5 M No 3/694(0.4) 0/287(0) 4/412(0.9) 9/584(1.5) 7/412(1.7) 4/533(0.7) 1/168(0.6) 3/141(2.1) 9/201(4.3) 
1.6 × 10−6 M Yes 1/185(0.5) 13/749(1.7) 1/478(0.2) 2/173(1.1) 5/239(2.0) 5/233(2.1) 6/148(3.9) 2/139(1.4) 6/140(4.1) 
1.6 × 10−6 M No 2/559(0.4) 7/552(1.3) 10/415(2.4) 2/240(0.8) 5/289(1.7) 2/150(1.3) 3/152(1.9) 2/138(1.4) 3/115(2.5) 
1.6 × 10−7 M Yes 11/231(4.5) 12/374(3.1) 0/247(0) 2/223(0.9) 3/123(2.4) 9/292(3.0) 10/167(5.6) 2/192(1.0) 10/158(5.9) 
1.6 × 10−7 M No 11/547(2.0) 2/652(0.3) 11/541(2.0) 3/241(1.2) 0/238(0) 7/294(2.3) 3/135(2.2) 2/153(1.3) 11/203(5.1) 
4. Cytotoxicity Assay Using Retinal Pigment Epithelial Cells 
4.1. Methods 
The cytotoxic effect of NK-5962 was tested by a cytotoxicity assay using CytoTox 96 
Non-Radioactive Cytotoxicity Assay (Promega, Madison, WI, USA) according to the man-
ufacturer’s instructions. In order to isolate retinal pigment epithelial cells at the 12-day 
old chick embryonic stage, the retinal pigment epithelium in the eye cups, after the re-
moval of the neurosensory retina, was incubated with 0.25% trypsin, 1 mM EDTA in Ca2+, 
and Mg2+-free Hanks’ balanced salt solution to peel off and disperse retinal pigment epi-
thelial cells. Retinal pigment epithelial cells at a cell density of 2 × 104 cells/100 μL of 
HEPES-buffered saline were incubated with 50 μL of varying concentrations of NK-5962 
for 4 h at room temperature in wells of a V bottom 96-well plate either under protection 
from light or under light from a fluorescent lamp at 320 lux (Figure 3). The final concen-
trations of NK-5962 in the solution were 6.6 × 10−5, 6.6 × 10−6, and 6.6 × 10−7 M. After cen-
trifugation of the plate at 250 × g for 4 min, 50 μL supernatants were transferred to wells 
of a U-bottom 96-well assay plate. A substrate mix for lactate dehydrogenase (LD) enzy-
matic reaction in 50 μL of assay buffer (phosphate-buffered saline containing 1% bovine 
serum albumin) was added to each well and incubated for 30 min at room temperature 
under protection from light. The absorbance at 490 nm was read with an EIA microplate 
reader after the addition of stop solution (1 M acetic acid). The negative control was de-
fined as spontaneous LD release (baseline) in the absence of NK-5962, while the positive 
control was defined as maximum LD release by the destruction of all cells in the presence 
of 10 μL of lysis solution (9% Triton X-100). All conditions were tested in four sets and a 
mean was obtained to calculate the percent cytotoxicity: 
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(measured value − baseline value) / maximum release) × 100  
The procedure was repeated six times to obtain six sets of values for statistical anal-
ysis [21]. 
 
Figure 3. Cytotoxicity assay for NK-5962 using chick retinal pigment epithelial cells. Top: Standard 
dark condition in a CO2 incubator and light condition made by placing a culture dish inside a bot-
tomless box with a lamp. Bottom: The percent cytotoxicity of retinal pigment epithelial cells incu-
bated for 4 h with NK-5962 at the concentrations of 6.6 × 10−5 M, 6.6 x 10−6 M, and 6.6 × 10−7 M under 
the protection from light or under light with a fluorescent lamp at 320 lux for 4 h. The values in all 
groups are negative, indicating cytoprotective effects of NK-5962. Percent cytotoxicity values are 
significantly smaller under the dark condition (P = 0.0289, two-factor ANOVA) but do not reach 
statistical significance in comparison among three different concentrations of NK-5962 (P = 0.0849). 
T bars indicate standard deviation. Modified from reference [21]. 
4.2. Results 
Retinal pigment epithelial cells isolated from 12-day embryonic chick eyes were in-
cubated with NK-5962 under the dark condition and the light condition for 4 h. The per-
cent cytotoxicity value was negative in all groups (Figure 3), indicating protective effects 
by NK-5962. Percent cytotoxicity values were significantly smaller under the dark condi-
tion (P = 0.0289, two-factor ANOVA) but did not reach statistical significance in compari-
son among the three different concentrations of NK-5962 (P = 0.0849, Figure 3) [21]. 
5. Intravitreous Injection of NK-5962 in RCS Rats 
5.1. Methods 
NK-5962 powder was dissolved in distilled deionized water at a concentration of 8.2 
μg/mL (16 μM). This original stock solution of NK-5962 (8.2 μg/mL) was diluted with 
saline (0.9% sodium chloride) to make a series of 10-fold dilutions from 8.2 × 10−4 to 8.2 
μg/mL. Twenty male pink-eyed RCS rats (RCS/Jcl-rdy/rdy, p-, CLEA Japan, Inc., Tokyo, 
Japan) at the age of 4 weeks were assigned to 5 groups (n = 4) that received NK-5962 at 5 
different concentrations. Intravitreous injection was performed twice at the age of 4 and 5 
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weeks (Figure 4A). This study was approved by the Animal Care and Use Committee at 
the Okayama University (Identifier OKU-2013441) and based on the Animal Welfare and 
Management Act in Japan. 
 
Figure 4. Intravitreous injection of NK-5962 in RCS rats’ eyes. (A) Time table for intravitreous injection of dye (NK-5962) 
solution in the left eye and control saline in the right eye of RCS rats twice at the age of 4 weeks and 5 weeks. (B) Four 
retinal sites defined for the analysis of apoptotic cell number. “a” and “b” begin at the straight distance of 373 μm and 160 
μm, respectively, superior from the optic nerve head. “c” and “d” begin at the straight distance of 160 μm and 373 μm, 
respectively, inferior from the optic nerve head. Modified from reference [22]. 
RCS rats were anesthetized by intraperitoneal injection of ketamine (87 mg/kg body 
weight, Daiichi Sankyo, Tokyo, Japan) and xylasine (13 mg/kg, Bayer Japan, Osaka, Ja-
pan). Mydriasis was induced by 0.5% tropicamide and 0.5% phenylephrine instillation 
(Santen Pharmaceutical, Osaka, Japan) and corneal anesthesia was further obtained with 
0.4% oxybuprokaine instillation (Santen Pharmaceutical, Osaka, Japan). Under a dissect-
ing microscope, 3 μL of NK-5962 solution and saline (0.9% sodium chloride) was injected 
into the vitreous of the left eye and the right eye, respectively, with a 30-gauge needle 
attached to a Hamilton syringe (50 μL 1705 LT SYR; Hamilton Company, Reno, NV, USA). 
The needle was inserted almost at a perpendicular angle and at 1mm from the corneoscle-
ral limbus to avoid the damage to the lens. Antibiotic (0.5% moxifloxacin, Novartis 
Pharma Japan, Tokyo, Japan) eye drops were instilled for both eyes. Each rat was housed 
in a standard rat cage in the 12 h light and dark cycle at the Animal Center of Okayama 
University. In a separate experiment, 3 rats were placed and maintained in constant dark-
ness after intravitreous injection of NK-5962 at a concentration of 8.2 μg/mL (16 μM). 
Apoptotic cells were detected by terminal deoxynucleotidyl transferase-mediated 
fluorescein-conjugated dUTP nick-end-labeling (TUNEL) assay, according to the manu-
facturer’s instructions (In Situ Cell Death Detection Kit, Roche Diagnostics, Mannheim, 
Germany). The images at the constant exposure time were captured by an Olympus 
FSX100 microscope that was equipped with the fluorescent filter cube U-MWIBA3. Five 
photographs in each of 5 retinal vertical sections per eye were taken and an entire frame 
(220 × 165 μm) of each photograph with ×40 NA0.95 objective lens was used for 
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measurements. The number of TUNEL-positive cells in the outer nuclear layer at each 
retinal site (a, b, c and d, Figure 4B) was counted in each frame of photographs. The num-
ber of TUNEL-positive cells per 1,000 μm2 of the outer nuclear layer was calculated for 
comparison by two-factor ANOVA. TUNEL-positive cell numbers were compared among 
the left eyes with NK-5962 injection at different concentrations and the right eyes with 
control saline injection [22]. 
5.2. Results 
Under 12 h light/dark cycle condition, in saline-injected eyes numerous TUNEL-pos-
itive cells were detectable in the outer nuclear layer where the nuclei of photoreceptor 
cells were located. In contrast, TUNEL-positive cells appeared to decrease in all four dif-
ferent sites (a, b, c and d) of retinal sections from NK-5962-injected eyes (Figure 5). 
TUNEL-positive cells in the outer nuclear layer were significantly different among differ-
ent concentrations of NK-5962 (P = 0.0001), but not significantly different among four dif-
ferent retinal sites (P = 0.144, two-factor ANOVA). TUNEL-positive cells in the outer nu-
clear layer of the NK-5962-injected eyes were significantly less at three higher concentra-
tions of NK-5962, ranging from 16 to 16 × 10−2 μM, compared to the saline-injected eyes (P 
= 0.0001, P = 0.0001, and P = 0.002, post hoc test, the least significant difference, Figure 6). 
 
Figure 5. Apoptotic cells in retinal outer nuclear layer of RCS rats’ eyes with intravitreous injection of NK-5962 at 12 h 
light/dark condition. TUNEL staining (green) of retinal sections (site b) of the eyes with intravitreous injections of 3 μL 
saline in the right eye or series of dilutions of the dye (NK-5962) stock solution in the left eye under 12 h light/dark cycle. 
Eyes were enucleated two weeks after the first injection at the age of 4 weeks. The nuclei were counterstained with DAPI 
(blue). The number of TUNEL-positive cells in the outer nuclear layer (ONL) was less in the dye-injected eyes than in the 
saline-injected eyes. INL, inner nuclear layer; OPL, outer plexiform layer; ONL, outer nuclear layer. Scale bar = 10 μm. 
Modified from reference [22]. 




Figure 6. Quantitative analysis of apoptotic cells in the retinal outer nuclear layer of each group of rats. TUNEL-positive 
cell counts per 1,000 μm2 in the outer nuclear layer of four different retinal sites (a, b, c, and d) of the left eye with dye 
(NK-5962) injection at five concentrations, compared to the right eye with saline injection under 12 h light/dark cycle. 
TUNEL-positive cell counts are significantly different among different dye (NK-5962) concentrations (P = 0.0001), but not 
significantly different among four different retinal sites (P = 0.144, two-factor analysis of variance, ANOVA). TUNEL-
positive cell counts in dye (NK-5962)-injected eyes were significantly less than in saline-injected eyes at the concentration 
of 16 μM (＊＊＊P = 0.0001), 16 μM x 0.1 (＊＊＊P = 0.0001), and 16 μM × 0.01 (＊＊P = 0.002). The bottom right panel shows 
TUNEL-positive cell counts in the eyes injected with dye (NK-5962 at 16 μM) versus saline under 12 h light/dark cycle and 
under 24 h constant dark condition. There is significant difference between dye (NK-5962)-injected eyes and saline-injected 
eyes under 24 h dark condition (＊＊＊P = 0.0001). T bars indicate standard deviation. Modified from reference [22]. 
In another series of experiments, RCS rats injected with saline and NK-5962 at a high-
est concentration (16 μM) were kept under constant dark conditions (Figure 7). The num-
ber of TUNEL positive cells in the outer nuclear layer was significantly different between 
NK-5962 injection and saline injection (P = 0.0001), but not significantly different among 
four different retinal sites (P = 0.982, two-factor ANOVA). As post hoc tests, the number 
of TUNEL-positive cells in the outer nuclear layer of the NK-5962-injected eyes was sig-
nificantly less than in the saline-injected eyes (P = 0.0001, Figure 6), but no significant dif-
ference was noted in the number of TUNEL positive cells between the constant dark con-
dition and the 12 h light/dark cycle (P = 0.411) [22].  




Figure 7. Apoptotic cells in retinal outer nuclear layer of RCS rats’ eyes with intravitreous injection of NK-5962 at 24 h 
dark condition. TUNEL staining of retinal sections at four different retinal sites (a, b, c, and d) in the left eye with dye (NK-
5962 at 16 μM) injection, compared with the right eye with saline injection under 24 h constant dark condition. INL, inner 
nuclear layer; OPL, outer plexiform layer; ONL, outer nuclear layer. Scale bar = 10 μm. Modified from reference [22]. 
6. Designing of Pharmacokinetic Studies 
According to the results of in vitro testing using chick retinal cells (Table 1) [21], the 
percentage of dead cells in the exposure to light was 2.78% in the absence of NK-5962, 
2.93% in the presence of 0.16 μM NK-5962, 1.89% in 1.6 μM, and 1.17% in 16 μM. The rate 
of the percentage of dead cells in each concentration of NK-5962 when compared with the 
absence of NK-5962 was 2.93/2.78 = 105% in 0.16 μM NK-5962, 1.89/2.78 = 68% in 1.6 μM, 
and 1.17/2.78 = 42% in 16 μM. The IC50 (50% inhibition concentration) is thus located be-
tween 1.6 μM and 16 μM and is calculated as 4.9 μM, based on values at two points. Since 
the experimental cell-culture system contained 10% fetal bovine serum (FBS), the ratio of 
non-binding form of NK-5962 is 0.34 (Table 2). The IC50 based on free form of NK-5962 is 
thus calculated as 1.7 μM. 
According to the results of intravitreous injection of NK-5962 in the eyes of RCS rats 
[22], the number of TUNEL-positive cells in the outer nuclear layer of the four retinal sites 
(a + b + c + d, Figure 4B) was used for calculation of EC50 (50% effective concentration). 
The percent ratio of the number of TUNEL-positive cells in 16 μM NK-5962 versus saline 
was 72/129 = 56% and the percent ratio of the number of TUNEL-positive cells in 1.6 μM 
NK-5962 versus saline was 85/139 = 61%. EC50 (50% effective concentration) would be 
around 16 μM. The intravitreous concentration following the injection of 16 μM NK-5962 
in the amount of 3 μL was calculated as 16 μM × 3 μL / (3 + 13) μL = 3 μM, based on the 
estimation that the volume of the rat’ vitreous cavity would be 13 μL. Although the esti-
mation of the IC50 and EC50, based on our previous studies [21,22], might be rough, the in 
vitro IC50 of 1.7 μM could, indeed, explain the in vivo EC50 of 3 μM.  
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7. In Vitro ADME Assay 
7.1. Solubility Assay 
The Japanese Pharmacopeia (JP) 1st fluid (pH 1.2) and JP 2nd fluid (pH 6.8) for dis-
solution testing were used for solubility measurements. The solution of a test compound 
was prepared by diluting 10 mM NK-5962 in 2 μL DMSO stock solution with 165 μL of JP 
1st or 2nd fluid and then mixed at 37 °C for 4 h by rotation at 1000 rpm. After loading the 
mixed solution into 96-well MultiScreen Filter Plates (product number MSHVN4510, 0.45 
μm hydrophilic PVDF membrane; Millipore, Bedford, MA, USA), filtration was per-
formed by centrifugation. The filtrates were mixed with acetonitrile and analyzed by high-
performance liquid chromatography-UV detection (HPLC-UV, 254 nm) or by liquid chro-
matography and tandem mass spectrometry (LC-MS/MS). Solubility was calculated by 
comparing the peak area of the filtrate mixture with that of a 100 μM standard solution. 
7.2. PAMPA (Parallel Artificial Membrane Permeability Assay)  
In order to determine the passive membrane diffusion rates, the Corning Gentest Pre-
coated PAMPA Plate System was used in the PAMPA test. The acceptor plate was pre-
pared by adding 200 μL of 5% DMSO/100 mM phosphate buffer (pH7.4) to each well and 
then 300 μL of 0.2 μM test compound in 5% DMSO/100 mM phosphate buffer (pH6.4) was 
added to the donor wells. The acceptor plate was then placed on top of the donor plate 
and incubated at 37 °C without agitation for 4 h. At the end of the incubation, the plates 
were separated and the solutions from each well of both the acceptor plate and the donor 
plate were transferred to 96-well plates and mixed with acetonitrile. The final concentra-
tions of compound in both the donor wells and acceptor wells, as well as the concentra-
tions of the initial donor solutions, were analyzed by LC-MS/MS. The permeability of the 
compound was calculated according to the previous report [23]. The recovery of the test 
compound was more than 90%. The permeabilities of antipyrine (100 μM), metoprolol 
(500 μM), and sulfasarazine (500 μM) as reference compounds, with 100%, 95%, and 13% 
gastrointestinal absorption in human [23], were 11, 1.5 and 0.034 × 10−6 cm/s, respectively. 
7.3. Hepatic Microsomal Stability Assay 
The disappearance of the parent compound over time was measured by using the 
amount of drug at time zero as a reference. After 5 min of preincubation, 1 mM NADPH 
(final concentration, the same applies to the following) was added to a mixture containing 
1 μM of the test compound, 0.2 mg/mL of rat or human liver microsomes (Sekisui Xe-
noTech, LLC, Kansas City, KS), 1 mM EDTA, and 100 mM phosphate buffer (pH 7.4) and 
then incubated at 37 °C for 30 min by rotation at 60 rpm. An aliquot of 50 μL of the incu-
bation mixture was sampled and added to 250 μL of chilled acetonitrile/internal standard 
(IS). After the centrifugation for 15 min at 3150 × g at 4 °C, the supernatants were analyzed 
by LC-MS/MS. Hepatic microsomal stability (mL/min/kg, CLint) was calculated according 
to the previous report [24] and 44.8 or 48.8 mg microsomal protein/g liver and 40.0 or 25.7 
g liver/kg body weight were used as scaling factors for the rat or human, respectively.  
7.4. Determination of the Unbound Fraction in Plasma and Medium 
An equilibrium dialysis apparatus, Rapid Equilibrium Dialysis (RED) Device Single-
Use Plate with Inserts, 8K MWCO (ThermoFisher Scientific, Waltham, MA, USA), was 
used to determine the unbound fraction for each compound in human plasma, rat plasma, 
and medium containing 10% fetal bovine serum (FBS). Plasma or medium was mixed with 
the test compound (1 μM) and 200 μL aliquots were loaded into the apparatus and dia-
lyzed versus 350 μL of 100 mM phosphate buffer (pH 7.4) at 37 °C for 4 h by rotation at 
1000 rpm. The unbound fraction was calculated as the ratio of receiver side (buffer) to 
donor side (plasma) concentrations.  
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7.5. Results of In Vitro ADME Assays 
As shown in Table 2, the solubility of NK-5962 was low at pH 6.8. Therefore, the 
evaluation of membrane permeability was performed at 0.2 μM. The membrane permea-
bility of NK-5962 by artificial membranes was lower than that of metoprolol, which has 
been reported to have 95% gastrointestinal absorption in humans [23]. The absorption of 
NK-5962 by oral administration was thus expected to be low and resulted in lower bioa-
vailability. Furthermore, the permeability of the blood-ocular barrier was not expected to 
be large. When human and rat liver microsomes were used, NK-5962 showed moderate 
metabolic stability. This result was also considered to be partly responsible for the low 
bioavailability. NK-5962 was stable in the absence of the coenzyme NADPH, suggesting 
that it is mainly metabolized by cytochrome P450. The protein binding rate was not dif-
ferent between the humans and rats. Furthermore, based on the unbound fraction in 10% 
FBS, 0.34 times the concentration of the added compound was considered to contribute to 
the drug effect in vitro. 










JP1 (pH 1.2) JP2 (pH 6.8) PAMPA  
(pH 6.5) 










0.028 0.022 0.34 
 
8. In Vivo Pharmacokinetics Assay 
8.1. Intravenous and Oral Administration 
Male Sprague Dawley (SD) and Wistar rats (5-week old) were obtained from Charles 
River Laboratories Japan (Yokohama, Japan) and Japan SLC, Inc. (Hamamatsu, Japan), 
respectively. All animals were maintained in air-conditioned quarters with room temper-
atures of 20 ± 2 °C, relative humidity of 50 ± 10%, and an alternating 12 h light/dark cycle. 
The rats were fed a certified diet MF (Oriental Yeast Co., Tokyo, Japan) and water ad libi-
tum. The studies were conducted in accordance with the guidelines provided by the An-
imal Care and Use Committee of Osaka University (Identifier DouyakuR01-3-1). 
A test compound (NK-5962) solution in 50% DMSO/water was injected intravenously 
(i.v.) to male SD rats. A test compound suspension in 0.5% methyl cellulose was adminis-
tered orally (p.o.) to male Wistar rats. The dosage of the test compound was 1 mg/2 mL/kg 
(i.v.) and 10 or 100 mg/10 mL/kg (p.o.). Blood samples were collected from the jugular 
vein at 5 and 15 min and 1 h (i.v.) by using pre-heparinized syringe after the intravenous 
administration or from the caudal vein at 15 and 30 min, 1, 2 and 4 h (p.o.) by using hep-
arinized capillary tube after the oral administration. At 30 min and 2 h (i.v.) or 8 h (p.o.), 
blood samples were collected from the abdominal aorta under isoflurane anesthesia and 
the eye balls and the whole brain were excised immediately. 
Plasma was prepared by centrifugation of the blood samples. Plasma and tissues 
were stored at −80 °C. The tissues were homogenized with a four-fold volume of phos-
phate-buffered saline to obtain a 20% tissue homogenate. Plasma and 20% tissue homog-
enates were precipitated with 4–20 volumes of acetonitrile/IS and centrifuged at 15,000 × 
g at 4 °C for 10 min. The supernatants were analyzed by liquid chromatography and tan-
dem mass spectrometry (LC-MS/MS). Standard non-compartmental analysis was per-
formed to determine the pharmacokinetic parameters: elimination half-life (t1/2) and area 
under the concentration time curve from time zero to infinity (AUC∞). The absolute bio-
availability (BA) of the oral dose was calculated as  
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AUC∞ (p.o.)/AUC∞ (i.v.).  
8.2. Topical Application as Eye Drops and Intravitreous Injection 
The NK-5962 solutions at 16 μM concentration in phosphate-buffered saline and at 
39.7 μM concentration in 0.5% methyl cellulose 400 solution (FUJIFILM Wako Chemicals, 
Osaka, Japan) were prepared as eye drops and topically applied to both eyes of two Wistar 
rats assigned for each concentration. The eyes were enucleated 30 min after topical appli-
cation, washed twice in saline, weighed, and frozen for NK-5962 measurement. In parallel, 
3 μL of the NK-5962 solution at 16 μM concentration in phosphate-buffered saline was 
injected into the vitreous of both eyes of 2 Wistar rats. The eyes in each rat were enucleated 
5 min and 2 h after the intravitreous injection, washed twice in saline, weighed, and then 
frozen. Both eyes of one rat served as the negative control. This study was approved by 
the Animal Care and Use Committee at Okayama University (Identifier OKU-2016267, 
OKU-2019196). 
8.3. LC-MS/MS Quantification Method for NK-5962 
Liquid chromatography and tandem mass spectrometry instrument (LC-MS8060) 
equipped with Shimadzu Nexera series LC system (Shimadzu, Kyoto, Japan) were used. 
All compounds were analyzed in multi-reaction monitoring mode under electron spray 
ionization conditions. The analytical column used was a CAPCELLPAK C18 MGIII (3 μm 
× 2.0 mmID × 35 mm; OSAKA SODA, Osaka, Japan) at 50 °C. The gradient mobile phase 
consisted of 0.1% formic acid in water (mobile phase A) and 0.1% formic acid in acetoni-
trile (mobile phase B) at a total flow rate of 1 mL/minute. The initial mobile phase compo-
sition was 10% B, which was held constant for 0.2 min, increased in a linear fashion to 90% 
B over 1 min, then held constant for 0.8 min, and then finally brought back to the initial 
condition of 10% B over 0.01 min and re-equilibrated for 1 min. The transitions (precursor 
ion > product ion) of NK-5962 and IS (methyl testosterone) are 433.2 > 279.2 and 303.1 > 
109.1 (positive), respectively. 
8.4. Results of Pharmacokinetic Studies 
After the intravenous administration of NK-5962 at 1 mg/kg body weight in rats, the 
plasma concentration of NK-5962 rapidly disappeared with the half-life of 0.35 h (Figure 
8, Table 3). Although the eye ball concentration of NK-5962 was lower than the plasma 
concentration, the eye ball concentration at 30 min after the intravenous administration 
was 29.8 nM, which was about four times higher than the value of 7.25 nM at 5 min after 
intravitreous administration. Based on our previous study that 3 uL intravitreous dose of 
NK-5962 at the concentration of 16 μM had the efficacy, the 1 mg/kg intravenous admin-
istration could have the drug effect. On the other hand, the absolute bioavailability of NK-
5962 in rats after the oral administration at 10 or 100 mg/kg was less than 1% (Figure 8, 
Table 4). The maximum plasma concentration after the oral administration of NK-5962 
was 17 nM, excluding the 8 h values which were too high to be suspected of contamination 
and the eye ball concentration was expected to be lower. At this setting, using the eye 
ball/plasma concentration ratio of 0.072 for the 8 h value, the maximum eye ball concen-
tration was expected to be as low as 1.3 nM. The eye ball concentration at 30 min after the 
topical application was 0.96 nM even at the higher dose of 39.7 μM. Based on these results, 
it is unlikely that the topical application up to 39.7 μM or the oral dose of 100 mg/kg might 
produce the drug effect. 




Figure 8. Pharmacokinetics of intravenous (i.v.) administration of NK-5962 1 mg/kg body weight 
and oral (p.o.) administration of NK-5962 10 mg and 100 mg/kg body weight in rats. NK-5962 con-
centrations in plasma are measured at designated time points. Graphs are created by excluding val-
ues which are suspected of contamination (Table 4). 
Table 3. Eye ball and plasma concentrations of NK-5962 after single intravitreous injection, topical application with eye 



















Intravitreous 16 μM (3 μL) 1-left 0.083 9.23 7.25   
  1-right 0.083 5.27    
  6-left 2 1.19 1.49   
  6-right 2 1.78    
Topical (Eye 
drop) 
16 μM (10 μL) 2-left 0.5 0.067 0.14   
  2-right 0.5 0.211    
  3-left (*dead) 0.5 0.222    
  3-right (*dead) 0.5 0.044    
Topical (Eye 
drop) 
39.7 μM (10 μL) 4-left 0.5 1.55 0.96   
  4-right 0.5 0.510    
  5-left 0.5 1.19    
  5-right 0.5 0.592    
Intravenous 1 mg/kg body 1-iv 0.083   779  
  2-iv 0.083   648  
  1-iv 0.25   511  
  2-iv 0.25   342  
  1-iv 0.5 34.1 29.8 661 0.052 
  2-iv 0.5 25.5  569 0.045 
  3-iv 1   49.9  
  4-iv 1   34.6  
  3-iv 2 4.16 3.79 24.3 0.17 
  4-iv 2 3.42  22.0 0.16 
*dead indicates that this rat died from deep anesthesia before the extirpation of both eyes.  
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Eye Ball/Plasma Ratio 
(Kp) 
10 1-po 0.25 2.42   
 2-po 0.25 1.71   
 1-po 0.5 1.51   
 2-po 0.5 1.90   
 1-po 1 2.11   
 2-po 1 2.26   
 1-po 2 1.51   
 2-po 2 1.76   
 1-po 4 0.80   
 2-po 4 1.20   
 1-po 8 *56.8 <0.1 Not calculated 
 2-po 8 1.69 <0.1 <0.059 
100 3-po 0.25 11.70   
 4-po 0.25 6.17   
 3-po 0.5 14.58   
 4-po 0.5 11.15   
 3-po 1 16.98   
 4-po 1 17.43   
 3-po 2 17.22   
 4-po 2 11.51   
 3-po 4 11.52   
 4-po 4 5.75   
 3-po 8 4.57 0.33 0.072 
 4-po 8 *44.4 0.40 Not calculated 
* values are remeasured but deemed erroneous by contamination. 
9. Reactive Oxygen Species (ROS) Assay 
9.1. Methods 
The ROS assay was designed to detect both singlet oxygen and superoxide generated 
from photo-irradiated chemicals [25–27]. Briefly, singlet oxygen was measured in aqueous 
solution by spectrophotometrically monitoring the bleaching of p-nitrosodimethylaniline 
at 440 nm using imidazole as a selective acceptor of singlet oxygen. Samples containing 
the tested chemical (20 or 200 μM), p-nitrosodimethylaniline (50 μM), and imidazole (50 
μM) in 20 mM sodium phosphate buffer (pH 7.4) were mixed in a tube. Each sample in 
200 μL was transferred into a well of a plastic 96-well plate (clear, untreated, and flat-
bottomed) and checked for precipitation under a microscope with an objective lens (×100) 
before light exposure. The plate was subjected to a measurement of absorbance at 440 nm 
using a microplate spectrophotometer. The plate was fixed in the quartz reaction con-
tainer with a quartz cover and then irradiated with the simulated sunlight (ultraviolet A/B 
and visible light, 250 W/m2, Suntest CPS plus, Atlas Material Testing Technology, Mount 
Prospect, IL, USA) for 1 h. After agitation on a plate shaker, the UV absorbance at 440 nm 
was measured. 
For the determination of superoxide, samples containing the test chemical (20 or 200 
μM) and nitroblue tetrazolium (50 μM) in 20 mM sodium phosphate buffer were irradi-
ated with the simulated sunlight for 1 h and the reduction in nitroblue tetrazolium was 
measured by the increase in absorbance at 560 nm in the same manner as the singlet oxy-
gen determination. Experiments were performed in triplicate wells in three independent 
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runs. As the final concentration, 200 μM test chemical solutions should be subjected to the 
ROS assay. However, when precipitation could be observed at 200 μM under the optical 
microscope, additional experiments should be performed under appropriate dilution (20, 
50, or 100 μM). When precipitation was observed at 20 μM in the reaction mixture, further 
experiments were not required. 
9.2. Results 
NK-5962 and NK-4 (1-ethyl-4-[(1Z,3E,5E)-1-(1-ethylquinolin-1-ium-4-yl)-5-(1-
ethylquinolin-4-ylidene)penta-1,3-dien-3-yl]quinolin-1-ium;iodide) [28–32] were tested in 
this study. Both NK-5962 and NK-4 showed a low level of reactive oxygen species gener-
ation (Table 5) and were concluded as less phototoxic from the viewpoint of drug candi-
dates. 
Table 5. Reactive oxygen species (ROS) assay for NK-5962 and NK-4. 
Compound Reactive Oxygen Species Generation 
 
Singlet oxygen 
(ΔA440 × 1000) 
Superoxide 
(ΔA560 × 1000) 
 mean ± standard deviation (n = 3) 
Quinine 200 μM (Positive control) 602 ± 7 348 ± 12 
Sulisobenzone 200 μM (Negative control) Not detected Not detected 
NK-4 20 μM 26 ± 2 42 ± 6 
NK-5962 20 μM 93 ± 14 Not detected 
10. Conclusions and Future Perspectives 
Based on our previous studies regarding the in vitro and in vivo efficacy of NK-5962 
[21,22], we performed in vitro ADME studies and designed pharmacokinetic studies. As 
for the efficacy of NK-5962 in preventing retinal neuronal death, the in vitro concentration 
in the assay using chick retinal cells in culture [21] can explain the effective dose of intrav-
itreous injection in the eyes of RCS rats [22]. The intravenous administration of NK-5962 
led to the appropriate concentration in the eye ball which would show the efficacy 
whereas the oral administration did not result in the effective concentration in the eye ball. 
Topical application of NK-5962 as eye drops also did not result in the effective concentra-
tion in the eye ball. These facts suggest that NK-5962 in the blood could penetrate the 
blood–ocular barrier and that NK-5962 could be absorbed in a small quantity through the 
gut. 
An ideal therapy for retinal dystrophy, such as retinitis pigmentosa, would be to stop 
the deterioration of the disease or at least to slow down the speed of the deterioration in 
a long-time span. At the moment, no drug is clinically available for this therapeutic pur-
pose to prevent retinal neurons from death, probably by apoptosis. NK-5962 would be a 
candidate drug to have retinal neuroprotection and, hence, can delay the deteriorative 
changes in retinal dystrophy. In our previous in vitro and in vivo studies, the effect of NK-
5962 to prevent retinal neurons from death by apoptosis did not depend on the presence 
of light [21,22]. NK-5962 is indeed a photoelectric dye, however, the efficacy to prevent 
retinal neurons from death by apoptosis would not be dependent on the effect of light. In 
this study, we showed additionally that NK-5962 did not have phototoxicity based on the 
novel standardized testing for reactive oxygen species assay [25–27]. Based on the lines of 
evidence, it can be assumed that the photoelectric property of NK-5962 would not be re-
lated with the effect of neuroprotection. We are in the ongoing process of transcriptome 
analysis by RNA-Seq in next generation sequencing to elucidate the molecular mechanism 
of neuroprotection induced by NK-5962. 
Oral administration or topical application such as eye drops would be better routes 
for drugs and would be expected to have the efficacy in a long term to slow down 
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deterioration in slowly-progressive chronic diseases, such as retinitis pigmentosa. How-
ever, the present pharmacokinetic studies showed poor penetrance of NK-5962 to the eye 
ball via oral administration and topical application with eye drops. The formula of eye 
drops with NK-5962 should be designed to enhance the intraocular penetrance to reach 
the effective concentration. High intraocular penetrance after the intravenous administra-
tion is a key factor in the design of a NK-5962 formula for oral administration. 
Regarding the photoelectric dye-based retinal prosthesis (OUReP), an investigator-
initiated clinical trial will be planned in patients with retinitis pigmentosa who have lost 
vision to light perception [33–35]. In parallel with the function of photoelectric dye-based 
retinal prosthesis, the neuroprotection by NK-5962 would be expected to play a role in 
maintaining the retinal tissue adjacent to the retinal prosthesis. In addition, NK-5962, as 
an adjunct therapeutic drug, would be administered to delay the deterioration of retinal 
dystrophy such as retinitis pigmentosa. 
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